Antiproliferative Effect of a Novel 4,4’-Disulfonyldiarylidenyl Piperidone in Human Colon Cancer Cells
The synthesis and antiproliferative effect of a novel curcumin analog, 4,4’-disulfonyldiarylidenyl piperidone, are reported. The design of the molecule is based on the fusion of an antiproliferative segment, namely diarylidenyl piperidone (DAP), with N-hyroxypyrroline, which is known to metabolically convert to nitroxide and protect healthy cells. Cellular uptake, metabolic conversion, cytotoxicity and antiproliferative effect of the DAP derivative against HCT-116 human colon cancer cells have been determined. Based on cell viability and proliferation assays as well as western-blot analysis of major transcription factors and inhibitory proteins, it is determined that the DAP compound is cytotoxic by inhibiting cell survival and proliferation pathways. The findings may have important implications in the design and development of effective anticancer agents.
KeywordsDisulfonyldiarylidenyl piperidone Colon cancer Rreactive oxygen species Nitroxide
This work was supported by the Hungarian Research Fund Grant OTKA FK 124331 and GINOP 2.3.2-15-2016-00049.
- 1.Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The International Journal of Biochemistry & Cell Biology, 41(1), 40–59.CrossRefGoogle Scholar
- 3.Dayton, A., Selvendiran, K., Kuppusamy, M. L., Rivera, B. K., Meduru, S., Kalai, T., Hideg, K., & Kuppusamy, P. (2010). Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biology & Therapy, 10(10), 1027–32.CrossRefGoogle Scholar
- 5.Selvendiran, K., Tong, L., Bratasz, A., Kuppusamy, M. L., Ahmed, S., Ravi, Y., Trigg, N. J., Rivera, B. K., Kalai, T., Hideg, K., & Kuppusamy, P. (2010). Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Molecular Cancer Therapeutics, 9(5), 1169–79.CrossRefGoogle Scholar
- 10.Selvendiran, K., Ahmed, S., Dayton, A., Kuppusamy, M. L., Tazi, M., Bratasz, A., Tong, L., Rivera, B. K., Kalai, T., Hideg, K., & Kuppusamy, P. (2010). Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells. Free Radical Biology & Medicine, 48(9), 1228–35.CrossRefGoogle Scholar
- 11.Selvendiran, K., Ahmed, S., Dayton, A., Kuppusamy, M. L., Rivera, B. K., Kalai, T., Hideg, K., & Kuppusamy, P. (2011). HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biology & Therapy, 12(9), 837–45.CrossRefGoogle Scholar
- 13.Rath, K. S., Naidu, S. K., Lata, P., Bid, H. K., Rivera, B. K., McCann, G. A., Tierney, B. J., Elnaggar, A. C., Bravo, V., Leone, G., Houghton, P., Hideg, K., Kuppusamy, P., Cohn, D. E., & Selvendiran, K. (2014). HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Research, 74(8), 2316–27.CrossRefGoogle Scholar